OOIR: Observatory of International Research

Papers

(The H4-Index of Atherosclerosis is 36. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Endothelial dysfunction in COVID-19: Current findings and therapeutic implications	196
Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability	92
Platelet-leukocyte interplay during vascular disease	88
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force	78
Systemic immune-inflammation index and incident cardiovascular diseases among middle-aged and elderly Chinese adults: The Dongfeng-Tongji cohort study	77
A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications	76
Insights into the regulatory role of circRNA in angiogenesis and clinical implications	75
Targeting HDAC6 attenuates nicotine-induced macrophage pyroptosis via NF-κB/NLRP3 pathway	65
Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene	63
EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, cross	61
APOE gene variants in primary dyslipidemia	61
High density lipoprotein functionality and cardiovascular events and mortality: A systematic review and meta-analysis	59
Trends in lipid-modifying agent use in 83 countries	58
Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective	54
Epicardial fat and coronary artery disease: Role of cardiac imaging	53
The dedicated “Lp(a) clinic”: A concept whose time has arrived?	50
Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK	50
Tissue factor in atherosclerosis and atherothrombosis	49
Carotid intima-media thickness should not be referred to as subclinical atherosclerosis: A recommended update to the editorial policy at Atherosclerosis	47
Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?	47
Apolipoprotein A-I concentrations and risk of coronary artery disease: A Mendelian randomization study	47
The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease: A systematic review and meta-analysis	46
Platelets as therapeutic targets to prevent atherosclerosis	46
Transendothelial transport of lipoproteins	45
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial	45

Shift work, and particularly permanent night shifts, promote dyslipidaemia: A systematic review and meta-analysis	43
Atherogenic index of plasma and the risk of rapid progression of coronary atherosclerosis beyond traditional risk factors	43
Lipoprotein(a) levels from childhood to adulthood: Data in nearly 3,000 children who visited a pediatric lipid clinic	40
Innate and adaptive immunity in cardiovascular calcification	40
HDAC3 protects against atherosclerosis through inhibition of inflammation via the microRNA-19b/PPARγ/NF-κB axis	39
Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease	39
South Asian ethnicity as a risk factor for coronary heart disease	39
Circulating ceramides as biomarkers of cardiovascular disease: Evidence from phenotypic and genomic studies	38
TRPA1 regulates macrophages phenotype plasticity and atherosclerosis progression	38
Non-genetic influences on lipoprotein(a) concentrations	37
Prognostic value of coronary artery calcium score, area, and density among individuals on statin therapy vs. non-users: The coronary artery calcium consortium	37
atherosclerosis: gone with the Wnt?	36
Marked plaque regression in homozygous familial hypercholesterolemia	36
Cardiac outcomes in patients with acute coronary syndrome attributable to calcified nodule	36
Existing and emerging strategies to lower Lipoprotein(a)	36
The impact of helical flow on coronary atherosclerotic plaque development	36
Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?	36